Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease

被引：3
|
作者：
Kim, Bo-Guen [1 ]
Kim, Sae Rom [2 ]
Jhun, Byung Woo [3 ]
机构：
[1] Hanyang Univ, Coll Med, Dept Internal Med, Div Pulm Med & Allergy, Seoul, South Korea
[2] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Pulm & Crit Care Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea
来源：
TUBERCULOSIS AND RESPIRATORY DISEASES | 2024年 / 87卷 / 02期
关键词：
LUNG-DISEASE;
D O I：
10.4046/trd.2023.0120
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：202 / 205
页数：4
相关论文
共 50 条
  • [1] Amikacin Liposome Inhalation Suspension in the Real-World Management of Refractory Mycobacterium avium Complex Pulmonary Disease
    Yanagihara, Toyoshi
    Ogata, Hiroaki
    Mori, Asami
    Kadowaki, Masako
    Moriuchi, Yuki
    Ishimatsu, Akiko
    Otsuka, Junji
    Taguchi, Kazuhito
    Moriwaki, Atushi
    Yoshida, Makoto
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [2] Real-world application of amikacin liposome inhalation in managing complex mycobacterium avium pulmonary conditions
    Yanagihara, Toyoshi
    Mori, Asami
    Ogata, Hiroaki
    Kadowaki, Masako
    Moriuchi, Yuki
    Ishimatsu, Akiko
    Otsuka, Junji
    Taguchi, Kazuhito
    Moriwaki, Atsushi
    Yoshida, Makoto
    RESPIROLOGY, 2024, 29 : 223 - 223
  • [3] Effects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With Refractory Mycobacterium avium Complex Pulmonary Disease
    Kurahara, Yu
    Yoshida, Shiomi
    Osugi, Asami
    Tanaka, Yuya
    Kobayashi, Takehiko
    Mitsuhashi, Toshiharu
    Kawasaki, Yohei
    Mitarai, Satoshi
    Tsuyuguchi, Kazunari
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [4] Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation
    Urabe, Naohisa
    Sakamoto, Susumu
    Tokita, Nozomi
    Yoshida, Hiromichi
    Usui, Yusuke
    Shimizu, Hiroshige
    Sekiya, Muneyuki
    Miyoshi, Shion
    Nakamura, Yasuhiko
    Isobe, Kazutoshi
    Kishi, Kazuma
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [5] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Matt Shirley
    Drugs, 2019, 79 : 555 - 562
  • [6] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
    Shirley, Matt
    DRUGS, 2019, 79 (05) : 555 - 562
  • [7] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Sheridan M. Hoy
    Clinical Drug Investigation, 2021, 41 : 405 - 412
  • [8] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Hoy, Sheridan M.
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 405 - 412
  • [9] Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection
    Zhang, Yang
    Hill, Adam T.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (06) : 737 - 744
  • [10] Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
    Sheridan M. Hoy
    Clinical Drug Investigation, 2021, 41 : 591 - 591
12345